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ABSTRACT
Immune and inflammatory cascades may play multiple roles in ovarian cancer. We aimed to identify
relationships between expression of immune and inflammatory mediators and patient outcomes. We
interrogated differential gene expression of 44 markers and marker combinations (n = 1,978) in 1,656
ovarian carcinoma patient tumors, alongside matched 5-year overall survival (OS) data in silico. Using
machine learning methods, we investigated whether genomic expression of these 44 mediators can
discriminate between malignant and non-malignant tissues in 839 ovarian cancer and 115 non-
malignant ovary samples. We furthermore assessed inflammation markers in 289 ovarian cancer
patients’ sera in the Swedish Apolipoprotein MOrtality-related RISk (AMORIS) cohort. Expression of the
44 mediators could discriminate between malignant and non-malignant tissues with at least 96%
accuracy. Higher expression of classical Th1, Th2, Th17, anti-parasitic/infection and M1 macrophage
mediator signatures were associated with better OS. Contrastingly, inflammatory and angiogenic
mediators, CXCL-12, C-reactive protein (CRP) and platelet-derived growth factor subunit A (PDGFA)
were negatively associated with OS. Of the serum inflammatory markers in the AMORIS cohort,
women with ovarian cancer who had elevated levels of haptoglobin (≥1.4 g/L) had a higher risk of
dying from ovarian cancer compared to those with haptoglobin levels <1.4 g/L (HR = 2.09, 95%
CI:1.38–3.16). Our findings indicate that elevated “classical” immune mediators, associated with response
to pathogen antigen challenge, may confer immunological advantage in ovarian cancer, while inflam-
matory markers appear to have negative prognostic value. These highlight associations between
immune protection, inflammation and clinical outcomes, and offer opportunities for patient stratification
based on secretome markers.
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Introduction
Ovarian cancer is a lethal gynecological malignancy with
5-year survival rates of <48% and few improvements in clin-
ical outcomes in the last decade.1,2 Complex interactions
between immune and cancer cells in the tumor microenvir-
onment involve multifaceted contributions of associated
secretomes,3 including critical roles in cancer progression
and survival.4,5 However, comprehensive evaluations of
immune mediator signatures in relation to disease progres-
sion are still required to help inform prognostic or predictive
algorithms for disease management.6
The immune system is capable of locating, recognizing and
ultimately eliminating tumor cells,7 and leukocytes play a major
role in these processes. For example, T helper lymphocytes
stimulate antigen-specific effector cells, enhance cytotoxic
immunity and recruit inflammatory cells to tumor sites.8
Macrophages can destroy cancerous cells by innate mechanisms
that involve secreted mediators such as interferon gamma
(IFNγ), granulocyte-macrophage colony-stimulating factor
(GM-CSF), and tumor necrosis factor alpha (TNFα).9
Macrophages can also be activated by antibodies to trigger anti-
body-dependent cellular cytotoxicity (ADCC) or phagocytosis
(ADCP).10–12 On the other hand, tumors evolve strategies to
evade immunological control, including reduced antigen pre-
sentation, upregulation of anti-apoptotic molecules, modified
cancer antigens arising from genomic instability and co-opting
immune cells to promote tumor proliferation and spread.
Ovarian cancer cells and tumor-associated fibroblasts may also
secrete mediators (e.g. IL-10, VEGF, TGFβ) which may
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moderate or modulate immune cell activation, promote regula-
tory T lymphocytes (Tregs) and alternatively activated M2
macrophages, to promote inflammation and wound healing
effects rather than activate classical immunity.13
Such juxtaposing contributions suggest that there is
a critical balance between anti-tumor and pro-tumor environ-
ments, which may often be tilted in favor of tumor growth
and escape from immunological surveillance.14,15 Previous
studies have identified specific immune mediators and path-
ways in patient sera, ovarian carcinoma ascites and tumor
lesions that may hold predictive or prognostic value.14,16–20
We hypothesized that a broader evaluation of secreted
immune, inflammatory and angiogenic mediator signatures,
reflecting the tumor-associated immunological environment,
may associate with differential clinical prognoses. In this
study, we selected 44 immune, inflammatory and angiogenic
mediators known to be involved in immune response to
pathogens. We analyzed associations with ovarian cancer by
machine learning methods in 954 samples that include 839
ovarian cancer tissues and 115 non-malignant ovary samples.
Furthermore, we evaluated the prognostic impact of differen-
tial gene expression of 1,978 immune and inflammatory med-
iator signatures from genomic expression data of 1,656
ovarian carcinoma patient tumors in silico. We also examined
serum inflammation mediators in 289 subjects diagnosed with
ovarian cancer from the Swedish AMORIS cohort.21 With
these, we explored any associations between different
immune, inflammation and angiogenesis mediator expression
profiles, with overall survival (OS).
Results
Identification of mediators with known or putative roles
in protective immunity and cancer-associated immune
responses
We aimed to determine whether relative elevated gene expres-
sion of immune-associated secreted mediators in patient tumors
was associated with ovarian cancer patient survival. A literature
search was conducted to select primary pre-clinical and clinical
studies in rodent models (mouse, rat), human cell lines, orga-
noid/3D models, and/or ex vivo evaluations with primary
human cells. Mediators (cytokines, chemokines, growth factors,
and secreted proteins) were selected and categorized based on
the following criteria: (a) reported association with known
immunological protection from pathogens, (b) evidence of asso-
ciation with and/or contribution to specific immunity type (e.g.
Th1/2/9/17, inflammation/angiogenesis); (c) shown to play spe-
cific roles (pro-tumoral/anti-tumoral) in rodent and human
xenograft models of cancer, in ovarian carcinomas and/or
other tumor types in different contexts (e.g. pre-clinical/clinical
experimental interventions such as prophylactic or curative
treatments, depletion or blockade with antibodies, siRNA/
shRNA, knock-out studies; studies of clinical data and human
samples reporting associations with patient outcomes). This
search identified 44 immune mediators (cytokines, chemokines,
mediators of inflammation and angiogenesis) associated with
distinct leukocyte subsets and immunological responses and
with known possible roles in cancer immunity (Supplementary
Table 1). Selected mediators were categorized into specific
immune signatures, namely Th lymphocyte subsets, anti-
parasitic/infection responses, macrophage polarization states,
and inflammation and angiogenesis (Figure 1).
A signature of combined immune and inflammatory
mediator expression can predict ovarian cancer from
non-malignant ovarian tissues
Machine learning models were used to investigate whether the
44 mediators selected by literature search were able to distin-
guish between non-malignant tissues and ovarian cancer tis-
sues. Three methods, Support Vector Machine, Random
Forest and Neural Network, were used. The set of 44 selected
mediator genes (‘Secretome mediator genes’ in Figure 2(a))
were able to discriminate between two classes (non-malignant
vs cancerous) with similar evaluation metrics when all 19,904
genes (‘All genes’ in Figure 2(a)) in the dataset were used as
prediction features (other metrics such as recall, sensitivity,
specificity, Matthew correlation coefficient, and F1-score are
reported in Supplementary Table 2). Although using ‘All
genes’ gave almost 100% accuracy in average for predicting
ovarian cancer, our ‘44 mediator genes’ also had more than
96% accuracy on average. The feature importance in the
Random Forest analysis identified that VEGF and PDGFA
were the most discriminant features among our 44 selected
genes in discriminating ovarian samples from controls (Figure
2(c)). Additionally, Linear Discriminant Analysis (LDA) using
our 44 mediator genes, showed clear segregation of ovarian
cancer and non-malignant tissues (Figure 2(b)).
Together, these findings highlight that the 44 gene signa-
tures selected for this study could distinguish non-malignant
ovarian tissues and ovarian cancer well.
High intratumoral expression of “classical” Th mediators
is associated with better 5-year overall survival
Using publicly available genomic datasets, we assigned tumor
specimens from 1,656 ovarian carcinoma patients into two
cohorts based upon the relative mRNA expression levels of an
immune mediator or mediator signature of interest. The top
25% of patients whose tumors expressed the highest levels of
a given mediator or combination of mediators were classified as
high expressing, while all other subjects were allocated to the low
expression group. The 5-year OS in the high and low expression
cohorts was compared. A follow-up of 5 years was selected based
on the low (<45%) 5-year survival expectancy for ovarian carci-
noma patients at diagnosis. Survival analyses were carried out for
the 44 markers identified by literature search, and for combina-
tions of up to four markers from each immune category. A total
of 1,978 tests, of the 44 markers or in combinations were exam-
ined in this study (Supplementary Figure 1; all HR and P-values
illustrated in Supplementary Figures 2, 3 and 4).
We evaluated whether high intratumoral expression of
immune mediators of the “classical” Th1, Th2, Th9 and
Th17 responses may have any associations with clinical out-
comes. Examination of individual mediators indicated that 9
out of the 22 mediators: CXCL-9, CXCL-10, CXCL-11, IFNγ,
TNFα, IL-4, MCP-1, IL-23, CXCL-13, were significantly
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associated with better patient survival compared with the
lower genomic expression group. Only one marker in this
cohort, TNFβ, was significantly associated with worse prog-
nosis (Hazard Ratio (HR) = 1.18, P= 0.043) (Figure 3(a),
Supplementary Figure 2A). The cytokines with the most
marked associations with better survival were CXCL-10 and
IFNγ, associated with 22% lower risk of death (CXCL-10: HR
= 0.78, P= 0.0037; IFNγ: HR = 0.78, P= 0.0036). Furthermore,
subjects with higher intratumoral expression of Th2 cyto-
kines, IL-4 and MCP-1, showed superior survival with 19%
and 17% reduction in risk of death, respectively (IL-4: HR =
0.78, P= 0.012; MCP-1: HR = 0.83, P= 0.029). Associations of
elevated expression of Th17 cytokines, IL-23 and CXCL-13,
with better 5-year OS were also observed, with 16% and 25%
reduction in risk of death, respectively (IL-23: HR = 0.84, P=
0.015; CXCL-13: HR = 0.76, P= 0.0017).
Overall, 89.4%, 42.9% and 33.3% of all combinations of up
to four mediators tested in the Th1, Th2 and Th17 categories,
respectively, were significantly associated with better patient
survival (Figure 3(b), Supplementary Figure 2B-D). In these
categories, TNFβ was the only marker out of a total of 255
analyses conducted with single and combined mediators that
was significantly associated with worse patient prognosis.
The greatest association with improved survival was
observed with high expression of Th1 cytokines (IFNγ (HR
= 0.78, P= 0.0036), CXCL-9 (HR = 0.81, P= 0.012), CXCL-10
(HR = 0.78, P= 0.0037) and CXCL-11 (HR = 0.8, P= 0.0078)),
and also when these mediators were combined (Figure 3(c)):
a combination of two mediators: CXCL-9 and CXCL-10 was
associated with an HR of 0.74 (P= 0.0006); the combination of
CXCL-9, CXCL-10 and CXCL-11 was associated with an HR
of 0.73 (P= 0.00028); and the highest improvement in patient
survival was measured with higher expression of all four
mediators (IFNγ, CXCL-9, CXCL-10, and CXCL-11) (HR =
0.72, P= 0.00021) (Figure 3(c)). These may point to synergistic
functions of these mediators that may confer survival benefits.
Together, these findings identify immune mediators of
“classical” (Th1, Th2, and Th17) responses, known to be
Figure 1. Schematic representation of immune and inflammatory mediators selected and categorized by immune response type.
A literature search was conducted to identify secreted immune mediators associated with different categories of immune activation with known possible roles in
cancer immunity. This identified 44 immune mediator markers (cytokines, chemokines, soluble inflammation and angiogenic factors), categorized into the following
groups: Th1, Th2, Th9, Th17, M1 macrophage, M2 macrophage, anti-parasitic/infection response (immune activation genes, in orange), and, angiogenesis and
inflammation (in blue) for evaluation of associations with patient survival in ovarian carcinoma.
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involved in protective immunity to bacteria and viruses, and
also those involved in pathogenic conditions such as allergies
and autoimmunity, that were associated with better prognosis
in the context of ovarian cancer.
High intratumoral expression of anti-parasitic/infection
immune mediators may confer improved patient survival
TNFα and MCP-1 are pro-inflammatory mediators, part of
the Th1 and Th2 secretomes, respectively, but are also
involved in anti-parasitic/infection immune surveillance.22–24
We sought to investigate whether high expression of these and
other mediators involved in these immune responses (n = 9),
could have prognostic value. In addition to TNFα and MCP-1
(TNFα: HR = 0.85, P= 0.046; MCP-1: HR = 0.83, P= 0.029),
high expression of the macrophage chemoattractant, CCL-7,
was also associated with improved patient 5-year OS (HR =
0.79, P= 0.005). One marker of the nine evaluated, CCL-21,
was significantly associated with worse prognosis (HR = 1.23,
P= 0.0092) (Figure 4(a), Supplementary Figure 3A). Of the
255 combinations of up to four mediators tested, 58.4% were
significantly associated with better OS, 36.9% were associated
with an HR<1, and 0.4% were significantly associated with
worse prognosis (Figure 4(b)).
When the three mediators most significantly associated with
better survival, CCL-7, TNFα, and MCP-1, were combined, the
best patient prognosis was associated with a combination of high
expression of CCL-7 and TNFα (HR = 0.77, P= 0.0024, reduc-
tion in risk of death of 23%) (Figure 4(c)). Furthermore, combi-
nation of any of these three mediators with high CCL-21
expression, which was independently associated with worse
patient prognosis in our evaluations, was often associated with
an improved patient survival (Figure 4(c)).
These findings provide support that immune signatures
known to be associated with responses to parasitic, viral or
bacterial infections may contribute to better patient survival
in ovarian cancer patients.
Elevated M1-type macrophage expression signatures are
associated with better patient outcomes
Macrophages comprise a substantial immune infiltrating
population in ovarian carcinoma lesions; however, their con-
tributions to anti-tumor responses have been long debated.
We analyzed immune signatures linked to classically activated
M1- and alternatively activated M2-macrophages, to assess
whether differential macrophage polarization states might
affect cancer progression and patient survival. Elevated
a b
c
Figure 2. Immune and inflammatory mediator signature can discriminate ovarian cancer from non-malignant ovarian tissues.
(a) Comparison of machine learning prediction accuracy for classifying healthy and ovarian tissue samples using three methods (Random Forest, Support Vector
Machine and Neural Network.). Comparisons were performed across all 19,904 genes (‘All genes’) and using the 44 selected genes (‘Secretome mediator genes’) as
features. SMOTE was applied to account for the imbalance in the sample size of the training dataset of a total of 954 samples (115 samples for non-malignant ovarian
tissue and 839 samples for ovarian cancer tissue), and a 5 times 10 fold cross-validation was performed. The average of 5 runs is shown ± the range of accuracies
derived across 5 runs. (b) Linear Discriminant Analysis (LDA) plot to illustrate discrimination of non-malignant and ovarian tissue samples with the 44 mediator genes.
(c) Ranking of 44 mediator genes using Random Forest feature importance with higher rank, suggests better discrimination across the two disease classes.
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tumor expression of M1-associated mediators was more likely
to be associated with improved prognosis than M2-related
signatures (Figure 5(a)). Overall, 74.7% of the eight M1 med-
iators and their combinations, were associated with signifi-
cantly improved 5-year survival, while only 2% of the seven
M2 mediators and their combinations had any significant
associations with improved survival (Figure 5(b,c)). The
remaining 80.6% of M2 mediator combinations showed HR
lower than 1. For both M1 and M2 signatures, some
combinations showed an HR greater than 1 (8.6% and
17.3%, respectively) (Figure 5(b), Supplementary Figure 3B
and 3C). Combining beneficial M1 mediators was associated
with a reduction of risk of death by as much as 29% (e.g.
TNFα, IL-12, CXCL-9, CXCL-11: HR = 0.71, P= 0.000068).
Combining M2 cytokines did not significantly alter the risk of
death, and the best patient outcome was associated with high
expression of IL-4 alone (HR = 0.84, P= 0.042, reduction of
risk = 16%) (Figure 5(c)). Overall, none of the M1 or M2
a
b
c
Figure 3. Elevated expression of mediators associated with Th1, Th2 or Th17 lymphocyte subsets is associated with improved 5-year overall survival in ovarian
cancer.
(a) Heatmap illustrating the association of elevated intratumoral expression of 22 individual cytokines in Th1, Th2, Th9 and Th17 categories, with 5-year overall
survival of ovarian cancer patients. HR < 1, indicates better survival of patients (depicted in dark green). HR > 1 indicates disadvantage to survival of patients (red).
HR of 1 indicates no prognostic value. (b) All combinations tested within Th1: n = 255, Th2: n = 98, and Th17: n = 30, are shown as pie chart and dot plot graphs. (c)
Heatmap illustrating the patient survival when up to four mediators that are independently associated with better prognosis (CXCL-9, CXCL-10, CXCL-11, and IFNγ)
are combined. The three combinations associated with the best prognosis are highlighted on Kaplan-Meier survival curves. (P-values: * = P < 0.05, ** = P < 0.01, ***
= P < 0.001, **** = P< 0.0001).
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mediator combinations were significantly associated with
worse survival in ovarian carcinoma.
These analyses suggest that high levels of M1-associated sig-
natures are more likely to confer a survival benefit in ovarian
cancer, while a markedly lower proportion of M2 mediator com-
binations are positively associated with better patient outcome.
Inflammatory and angiogenic mediator expression in
patient tumors shows negative or no association with
patient survival
We next considered whether mediators in inflammation and
angiogenesis may be associated with clinical prognosis in ovar-
ian cancer. Of the 13 markers evaluated in this category, inde-
pendently elevated expression of CXCL-12 (HR = 1.48, P=
1.4x10−7), C-Reactive Protein (CRP) (HR = 1.25, P= 0.0049)
and Platelet Derived Growth Factor subunit A (PDGFA) (HR
= 1.19, P= 0.032) were significantly associated with negative
prognostic outcomes in patients; the mediators were associated
with increased risk of death by 48%, 25%, and 19%, respectively
(Figure 6(a), Supplementary Figure 4).
Furthermore, high expression of 16.5% of the 1,092 com-
binations of mediators in this immune category was signifi-
cantly associated with worse patient prognosis (52.3% were
associated with HR>1 without statistical significance), while
1.4% were significantly correlated with positive prognosis
(Figure 6(b)). CXCL-12 was the mediator most significantly
associated with worse clinical outcome alone and in combina-
tion with other inflammation markers (Figure 6(c)).
Inflammatory markers in patient sera show association
with ovarian cancer-specific death
We next considered whether markers of inflammationmeasured
in the circulation were also associated with an increased risk of
death from ovarian cancer using the AMORIS cohort.
Characteristics of study participants are shown in Table 1.
During a mean follow-up of 6.5 years, 177 out of 289 women
diagnosed with ovarian cancer died specifically from ovarian
cancer. The mean value of CRP in serum was higher in women
who died from ovarian cancer (11.67 mg/L) (n = 177) compared
with women who did not (7.11 mg/L) (n = 112) (Table 1). Cox
a
b
c
Figure 4. High expression of anti-parasitic/infection response mediators is associated with better patient survival.
(a) Heatmap illustrating the association of elevated intratumoral expression of 9 individual cytokines in the anti-parasitic clearance category, with 5-year overall
survival in ovarian cancer patients. HR < 1, indicates better survival of patients and (dark green). HR> 1 indicates disadvantage to survival of patients (depicted in
red). HR = 1 indicates no prognostic value. (b) All tested combinations of mediators involved in anti-parasitic/infection response (n = 255) shown as pie chart and dot
plot. (c) Heatmap illustrating the patient survival when up to four mediators that are independently associated with better prognosis (CCL-7, CCL-21, TNFα, and MCP-
1) are combined. The three combinations associated with the best prognosis are depicted in Kaplan-Meier survival curves. (P-values: * = P < 0.05, ** = P< 0.01, *** =
P< 0.001, **** = P< 0.0001).
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proportional hazards regression analysis showed a positive asso-
ciation with risk of dying from ovarian cancer for those with
higher levels of serum haptoglobin (≥1.4 g/L) compared to those
with haptoglobin levels <1.4 g/L (HR = 2.09, 95% CI:1.38–3.16)
(Figure 6(d), Table 2). The median survival time for ovarian
cancer was 1.3 years shorter whenwomen had haptoglobin levels
≥1.4 g/L compared to women with haptoglobin levels <1.4 g/L.
After a follow-up time of 20 years, 15% of the women with
haptoglobin levels ≥1.4 g/L had survived ovarian cancer com-
pared to 39% of the women with haptoglobin levels <1.4 g/L (log
Rank P-value <0.001). No significant associations were observed
with serum CRP, albumin or leukocytes (Figure 6(d), Table 2).
Collectively, these findings may suggest that elevated cancer-
associated inflammation markers, in the tumor and patient
circulation, may have negative associations with patient survival
in ovarian cancer.
a
b
c
Figure 5. High expression of intratumoral M1 markers are more likely to be associated with improved survival than M2 markers.
(a) Heatmaps illustrating the association of elevated intratumoral expression of M1 and M2- type macrophage-related mediators, with 5-year overall survival in
ovarian cancer patients. HR < 1, indicates better survival of patients and (depicted in dark green). HR > 1 indicate disadvantage to survival of patients (depicted in
red). HR = 1 indicate no prognostic value. (b) All tested combinations within M1 (n = 162) and M2 (n = 98) shown as pie chart, dot plot and heatmaps. (c) The three
combinations from each category associated with the best prognosis are depicted in Kaplan-Meier survival curves. (P-values: * = P< 0.05, ** = P< 0.01, *** = P<
0.001, **** = P< 0.0001).
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Higher intratumoral expression of immune activation
markers may rescue or neutralize the negative
associations of inflammation or angiogenesis
Based on the differences in patient survival associated with
mediators of immune activation compared to those of inflam-
mation and angiogenesis, we sought to investigate whether
intratumoral signatures of classical, anti-parasitic/infection
and M1/M2-type macrophage immune responses could influ-
ence the associations of inflammatory and angiogenesis sig-
natures with worse clinical prognosis. Mediators
independently associated with better survival were selected
from each immune category (namely CXCL-13, IL-23,
CXCL-9, CXCL-10, CXCL-11, TNFα, IFNγ, CCL-7, MCP-1,
and IL-4) and combined with each of the three inflammation
and angiogenesis mediators associated with the worst patient
survival (CXCL-12, CRP, PDGFA) (n = 43 tests, of which n =
30 were combinations, Figure 6(e)). Combination of high
expression of any of the classical, anti-parasitic or macro-
phage immunity mediators with PDGFA and/or CRP was
associated with either reduction of HR or reversal towards
better prognosis (Figure 6(e)). This effect was particularly
apparent when Th1/M1 mediators, CXCL-9, CXCL-10, and
CXCL-11, were included. On the other hand, high expression
of CXCL-12, combined with any classical immune mediator,
continued to retain a negative association with patient survi-
val, however, combination with high CXCL-9 and CXCL-10
a
c
d e
b
Figure 6. Elevated expression of inflammation and angiogenic markers is associated with no effect or worse survival.
(a) A heatmap illustrating the association of elevated intratumoral expression of 13 individual cytokines of inflammation and angiogenesis, with 5-year overall
survival in ovarian cancer patients. HR < 1, indicates better survival of patients (depicted in dark green). HR > 1 indicates disadvantage to survival of patients
(depicted in red). HR = 1 indicates no prognostic value. (b) All tested combinations within inflammation and angiogenesis category (n = 1,092) shown as pie chart
and dot plot. (c) Heatmap illustrating the patient survival when up to four mediators that are independently associated with better prognosis (CRP, CXCL-12, IL-36,
and PDGFA) were combined, and three example Kaplan-Meier survival curves of signatures associated with the worst prognosis. P-values: * = P< 0.05, ** = P< 0.01,
*** = P< 0.001, **** = P< 0.0001). (d) Kaplan-Meier survival curves illustrating the association of serum C-reactive protein (CRP) (≥10mg/L or <10 mg/L) and
haptoglobin (<1.4 g/L or ≥1.4 g/L) levels with ovarian cancer patient survival in the AMORIS cohort (n = 177 patient sera). (e) Heatmap illustrating the patient
survival when high expression of mediators involved in immune activation (Th1, Th2, Th17, M1, M2 and anti-parasitic/infection clearance), that are independently
associated with better survival, are combined with high expression of inflammation and angiogenesis mediators that are independently associated with the worst
prognosis (n = 30 combinations). (P-values: * = P< 0.05, ** = P< 0.01, *** = P< 0.001, **** = P< 0.0001).
e1593811-8 M. NAKAMURA ET AL.
expression, appeared to partly “neutralize” its negative prog-
nostic association.
Overall, these suggest that combined high intratumoral
expression of mediators of classical immune responses, along-
side inflammation signatures otherwise associated with poor
prognosis, may moderate, reduce or reverse the negative asso-
ciations of inflammation and angiogenic mediators with
patient survival.
Discussion
We investigated immune and inflammatory mediator expres-
sion signatures and their clinical significance in ovarian can-
cer. We identified 44 mediators known to be involved in
immune response to pathogens and in inflammation. In 954
samples, including 839 ovarian cancer tissues and 115 non-
malignant ovarian tissue samples, we found that gene expres-
sion of the 44 mediators could differentiate between ovarian
cancer and non-malignant tissues with 96–98% accuracy, by
machine learning methods. By evaluating immune and
inflammatory mediator gene expression profiles from 1,656
ovarian carcinoma patient tumors in silico, we demonstrated
that higher genomic expression of some classical Th1, Th2,
Th17, anti-parasitic/infection and M1-macrophage associated
secreted mediator signatures were associated with better clin-
ical outcomes. Contrastingly, we found negative associations
of the intra-tumoral genomic expression of inflammatory and
angiogenic markers with ovarian cancer patient OS. In con-
cordance, the inflammation marker haptoglobin in the sera of
289 ovarian cancer patients from the AMORIS cohort showed
a negative association with survival. Our study therefore high-
lights links between immune protection and inflammation
mediator signatures with ovarian cancer outcomes.
The association of immune-related gene signatures to dis-
ease subgroups is critical in understanding disease mechan-
isms and prognosis.25 Supervised learning such as machine
learning methods employed here, are increasingly popular
means of computational classification of cancer samples into
appropriate phenotypes and ranking the discriminatory power
of each gene in the disease classification outcome.26 When
machine learning was used to discriminate between non-
malignant and cancerous samples, excellent prediction accu-
racy was reported when the set of 44 selected genes was used.
Through LDA, the ovarian cancer samples clearly separated
from non-malignant tissues, illustrating that the selected 44
mediators are efficient discriminatory features. These indicate
that the selected genes (features) are able to classify tissue
types and supports the importance of these published litera-
ture-selected markers.
Elevated intratumoral expression of Th1 immune media-
tors, CXCL-9, CXCL-10 and CXCL-11 – which share the
same receptor, CXCR3 – were associated with better prog-
nosis. Consistent with our findings, the CXCL-9/CXCL-10/
CXCL-11–CXCR3 axis has been reported to lead to enhanced
tumor growth restriction by recruitment of CD8 + T cells
(CTLs), NK cells and macrophages.27–31 In mouse models,
CXCL-11, as an adjuvant to oncolytic virus-based treatments,
could significantly enhance their anti-tumor efficacy,29 and
CXCL-11-Fc fusions enhanced recruitment of antigen-specific
CD8 + T cells.32 Furthermore, secretion of these three med-
iators by monocytes, endothelial cells, fibroblasts and cancer
cells was enhanced through transcriptional activation of
STAT1 and NFκB, caused by IFNγ and TNFα working in
synergy.33 In our study, elevated expression of both IFNγ
and TNFα were also associated with better 5-year OS, point-
ing to putative anti-tumor functions.
We observed that IL-4, a key Th2-secreted cytokine that
mediates lymphocyte differentiation and orchestrates allergic
diseases, was significantly associated with better prognosis.
Although IL-4 has been linked with pro-tumor properties,34–
36 mice overexpressing IL-4 showed significant tumor growth
reduction compared to non-transgenic mice,37 and there are
reports of inverse correlations between allergic conditions and
the risk of developing certain types of cancer including ovar-
ian cancer.38–40 Here, the positive prognostic association of
IL-4 and some Th2 signatures may suggest potential anti-
tumor functions in ovarian carcinomas.
Both IL-23 and CXCL-13 may facilitate pro-tumor pheno-
types through initiating tumorigenesis, increasing
angiogenesis,41 promoting metastasis42 and reducing infiltra-
tion of CD8 + T cells43 in colorectal and non-small cell lung
carcinoma (NSCLC), and by maintaining self-renewability of
Table 1. Descriptive statistics of study population from the AMORIS cohort.
Ovarian cancer-
specific death
N = 177
No deaths specific to
ovarian cancer
N = 112
Mean Age, years (±SD) 61.4 (±11.81) 57.7 (±11.40)
Mean time between sampling and
diagnosis, months (±SD)
24.5 (±18.55) 27.1 (±18.53)
Mean follow-up time, years (±SD) 2.7 (±3.06) 12.5 (±6.23)
C-reactive protein (mg/L)
Mean, mg/L (±SD) 11.67 (±20.41) 7.11 (±10.22)
<10 mg/L, n (%) 139 (78.5%) 94 (83.9%)
≥10 mg/L, n (%) 38 (21.5%) 18 (16.1%)
Albumin (g/L)
Mean, g/L (±SD) 41.54 (±3.03) 41.76 (±3.02)
<40 g/L, n %) 35 (19.8%) 20 (17.9%)
≥40 g/L, n (%) 136 (76.8%) 86 (76.8%)
Missing, n (%) 6 (3.4%) 6 (5.4%)
Leukocytes (x109 cells/L)
Mean, x109 cells/L (±SD) 6.80 (±1.86) 6.99 (±2.02)
<10 × 109 cells/L, n (%) 85 (48.0%) 58 (51.8%)
≥10 × 109 cells/L, n (%) 4 (2.3%) 4 (3.6%)
Missing, n (%) 88 (49.7%) 50 (44.6%)
Haptoglobin (g/L)
Mean, g/L (±SD) 1.31 (±0.55) 1.12 (±0.37)
<1.4 g/L, n (%) 72 (40.7%) 59 (52.7%)
≥1.4 g/L, n (%) 34 (19.2%) 11 (9.8%)
Missing, n (%) 71 (40.1%) 42 (37.5%)
Table 2. Age-adjusted hazard ratio (HR) for risk of ovarian cancer-specific death
in the AMORIS cohort with 95% confidence intervals (CI) using Cox proportional
hazards model.
Hazard Ratio (95% Cl)
C-reactive protein (mg/L)
<10 mg/L 1.00 (Ref)
≥10 mg/L 1.18 (0.82–1.69)
Albumin (g/L)
<40 g/L 1.10 (0.75–1.61)
≥40 g/L 1.00 (Ref)
Leukocytes (x109 cells/L)
<10 × 109 cells/L 1.00 (Ref)
≥10 × 109 cells/L 0.88 (0.32–2.41)
Haptoglobin (g/L)
<1.4 g/L 1.00 (Ref)
≥1.4 g/L 2.09 (1.38–3.16)
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ovarian cancer stem cells (OCSCs) within the tumor
microenvironment.44 In our analyses, we found a significant
correlation between higher expression of the Th17 differentia-
tion cytokine IL-23 with better OS, in line with a study by
Wolf et al.45 We also found that higher expression of the
chemokine CXCL-13 was also associated with better OS in
our cohort. There are no reports with regards to beneficial
effects of CXCL-13 in ovarian cancer, however, links with
improved outcome have been observed in HER2+ breast
cancer patients.46 Combined with results of our study these
associations suggest possible anti-tumor rather than tumor-
promoting roles for IL-23 and CXCL-13 in the ovarian cancer
context and warrant further investigation.
We also found positive prognostic associations with ele-
vated levels of TNFα and MCP-1, immune mediators involved
in Th1 and Th2 immunity, respectively, but also in anti-
parasitic/infection responses. MCP-1, a potent monocyte che-
moattractant can support anti-parasitic immunity, enhancing
monocyte/macrophage and cytotoxic T cell migration and
retention into infected tissues, and facilitating parasite uptake
and destruction by macrophages.47 MCP-1 may recruit classi-
cal monocytes from nearby blood vessels that may differenti-
ate into immune-activating M1 macrophages, which may
suppress tumor growth and development.48 We recently iden-
tified an IgE-potentiated TNFα/MCP-1 axis associated with
tumor growth restriction mediated by activated macrophages
in vivo.11,12,49 Here, our analyses in ovarian cancer tumor
samples also indicate that a TNFα/MCP-1 signature could
have a role in anti-cancer immunity. This and other immune
signatures normally deployed in infection clearance may
potentially be enhanced by specific immunotherapy
approaches such as a tumor-specific IgE or by attenuated
parasite vaccines,50,51 to reverse immunosuppression and con-
fer therapeutic benefits in ovarian and other cancers.
A broad spectrum of activation states is exhibited by tumor-
associated macrophages (TAMs); the two extremes of which
are classically activated M1 and alternatively activated M2
phenotypes.52 Our analyses indicated that the majority of M1-
type macrophage mediators were associated with improved
prognosis, while only 2% of M2-type markers significantly
correlated with better survival. These likely reflect distinct
roles of classically- and alternatively activated macrophages
within the tumor microenvironment. M1-type macrophages
have both direct and indirect tumoricidal effects: direct effects
by release of reactive oxygen and nitrogen intermediates, lead-
ing to tumor cell cytotoxicity and anti-proliferative effects;53
and indirect effects by enhancing T cell- and NK-driven anti-
tumor immunity through secreting cytokines such as CXCL-9,
CXCL-10, CXCL-11, IL-23 and TNFα. M1-produced factors
thus establish a highly cytotoxic, tumor-rejecting
environment.53 By contrast, alternatively activated M2-type
macrophages may fail to elicit potent immune responses
against cancerous cells, leading to neovascularization, cancer
spread and local suppression of innate and adaptive anti-tumor
immune responses.54 M2 mediators such as TGF-β, CCL-17
and CCL-22 may inhibit Th lymphocytes, CTLs, NK cells,
macrophages, B cells and antibody synthesis, and support can-
cer cell proliferation and tumor angiogenesis.55,56 Despite these
proposed pro-tumoral functions, our study demonstrates that
over 97% of the M2 combinations were not associated with
patient survival outcomes, perhaps pointing to tolerance to
rather than promotion of tumor growth. These may suggest
that re-education of macrophages toward an M1-like functional
phenotype might offer therapeutic advances.10,49,57,58
Inflammation has been linked to the risk of cancer develop-
ment in a range of malignancies. Components of inflammation
have been reported to contribute to proliferation, migration
and survival of ovarian cancer cells through mutations, geno-
mic instability and epigenetic modifications, or by stimulating
tissue repair, angiogenesis and causing localized immunosup-
pression (Supplementary Table 1). However, inflammatory cells
and molecules can also drive effective anti-cancer immunity
capable of eradicating cancer or delaying its development.59 In
our Random Forest analysis, VEGF and PDGFA were of the
highest importance among the 44 selected genes in discrimi-
nating cancer from non-malignant ovary tissue and elevated
CXCL-12, CRP and PDGFA, were significantly associated with
worse prognosis in our study of intratumoral expression.
CXCL-12, likely secreted by cancer-associated fibroblasts
(CAFs), may promote accumulation of FoxP3 + T cells and
cancer cell survival in high grade serous ovarian cancer.60
Moreover, binding of CXCL-12 to its receptor CXCR4 has
been shown to induce tumor proliferation and cancer progres-
sion, and these effects were attenuated when this pathway was
knocked down in pre-clinical in vivo models.61 PDGFA is
a potent activator for mesenchymal-origin cells, and stimulates
chemotaxis, proliferation and angiogenesis in cancer,62 enga-
ging several pathways such as Ras-MAPK, PI3K, PLCγ and
inducing VEGF production.62,63 Plasma CRP concentration is
increased in response to inflammation, tissue damage and
infection, and may promote tumor growth and metastasis by
causing low-grade inflammation in breast cancer, although the
exact pathogenesis is still uncertain.64,65 In our analyses, we
report a significant association between high intratumoral CRP
expression with poor patient prognosis. Comparably, in the
Swedish AMORIS cohort, during a mean follow-up of 6.5
years, the mean serum CRP levels measured around the time
of diagnosis were higher in women who subsequently died
from ovarian cancer. This is consistent with previous reports
of elevated serum CRP associated with a higher risk of devel-
oping ovarian cancer.66 Furthermore, increased serum levels of
the inflammation marker haptoglobin was significantly asso-
ciated with poorer survival, aligning with reports pointing to
haptoglobin as a potential serum biomarker in ovarian
cancer.67,68 Although the mechanism of how haptoglobin con-
tributes to cancer progression is not yet clear, evidence points
to contributions to ovarian cancer cell migration, through cell
morphology and alterations in actin cytoskeleton.69 Based on
analyses of three cohorts, our findings therefore point to sig-
nificant roles of inflammation and angiogenesis mediators in
ovarian cancer patient circulation and tumors.
Independently, high intratumoral expression of the Th1
cytokine TNFβ and of the anti-parasitic mediator CCL-21
was significantly associated with worse prognosis. When com-
bined with high expression of other cytokines in the same
immune category, we noted reductions in HR (HR<1).
Furthermore, combined mediators of immune activation
(which individually were associated with positive prognosis)
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with markers of inflammation and angiogenesis (which were
independently associated with worse survival), could neutra-
lize or reverse some of the negative prognostic associations of
inflammation and angiogenic markers. From these observa-
tions, it is tempting to speculate that potential therapeutic
approaches able to activate specific immune signatures or
reverse immunosuppression may be desirable.
Taken together, our analyses integrating: (a) selection of
44 secreted mediators involved in immune responses and
inflammation through literature search, (b) gene expression
by machine learning methods in 954 ovarian cancer and
non-malignant ovary tissues, (c) 1,978 immune and inflam-
matory mediator signatures from genomic expression data
of 1,656 ovarian carcinoma patient tumors, and (d) 289 sera
from patients with ovarian cancer in the AMORIS cohort
study, all point to the significance of immune secretomes
for clinical outcomes. Immune activation, whether classical,
anti-parasitic, or supporting macrophage re-education to
classically activated phenotypes, may provide an immuno-
logical advantage in ovarian cancer, and inflammatory and
angiogenic signatures may contrastingly confer negative
effects for prognosis. Even the negatively prognostic ele-
vated expression of inflammatory or angiogenic mediators
may be “neutralized” when expressed along with beneficial
secretome states and could be taken into consideration in
immunomonitoring and when developing or selecting
therapies.20 Future work could focus on the roles of specific
immunological states in patient cohorts, including different
malignant histologies, or stratification of treatment-naïve,
chemotherapy or immunotherapy pre-treated patients.
These may help identify common secretome algorithms
linked to improved survival. Insight into these interactions
and immune signatures can facilitate the development of
novel tailored immunotherapies that seek to enhance bene-
ficial host immunity.
Materials and methods
Selection of immune cell markers for analysis
We performed an extensive literature review focusing on
secreted immune mediators associated with different cate-
gories of immune activation with reported possible roles in
cancer immunity and we identified 44 immune mediator
markers (cytokines, chemokines and soluble inflammation
and angiogenic factors). These 44 markers were categorized
into the following groups: Th1, Th2, Th9, Th17, M1 macro-
phage, M2 macrophage, anti-parasitic/infection response, and,
angiogenesis and inflammation (Figure 1, Supplementary
Table 1).
Microarray gene expression data analysis for malignant
disease classification
A dataset of 954 samples that includes 839 ovarian cancer
tissues and 115 non-malignant samples was obtained from
Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/
geo/) Affymetrix Platform GPL570 (HG-U133 Plus 2.0)
(GSE_IDs from previous reports).70 The microarray data of
Affymetrix chips consists of a series of CEL files containing
raw intensities for each probe on the array. Probe intensity
was normalized by applying the R BioConductor RMA
(Robust Multichip Average) function.71 Probes were mapped
to genes using Affymetrix Human Genome U133 Plus 2.0
Array notation data (chip HG-U133 Plus 2) and in cases
where multiple probes were mapped to the same gene,
probe intensities were averaged.
Assessing ability of selected 44 markers to differentiate
between ovarian cancer and non-malignant tissue
through machine learning
Three popular machine learning methods, Support Vector
Machine, Random Forest, and Neural Networks were
applied to classify ovarian cancer and non-malignant tissue
samples using either all the genes available from the data-
base, or just the 44 mediator genes as prediction features.
These models were implemented using Python Scikit-Learn
library. All the experiments were run on a workstation with
a 12-core Intel Core i7 and 32GB of memory running
Ubuntu Linux 16.04. For Support Vector Machine, we
used Scikit-Learn svm.SVC function with “linear” kernel
and 1.0 penalty error parameter (C). Similarly,
RandomForestClassifier with 900 trees in the forest (n_esti-
mator parameters) and MLPClassifier for the implementa-
tion of neural networks with two layers of size 800 and 100,
“adam” solver, 0.01 initial learning rate, and 1e-5 regular-
ization parameter (“alpha”) were used. After the random
forest classifier was trained, “feature_importances_attribute”
was used to determine the importance of each feature in the
classification.
Linear Discriminant Analysis (LDA) was used to map
high-dimensional input data into a two-dimensional space
and visualize them. Visualization is a common way of sum-
marizing data to show the ability of the input features to
represent the labels. LDA extracts a linear combination of
input features that distinguish the tissue type classes.72 In
terms of the cross-validation scheme of the machine learning
experiment, we performed 5 times 10 fold cross validation,
where samples (954) were split into two sets of training and
test sets (90/10 data split). Since the gene expression data have
a large ratio of number of features vs. number of samples, we
performed oversampling on our imbalanced dataset by apply-
ing SMOTE (Synthetic Minority Over-sampling Technique,
SMOTE function in imbalanced-learn 0.4.2 Python package)
on the training dataset to avoid overfitting.73 The model is
built on the training set and then accuracy is assessed on the
test set. In terms of ranking the importance of the 44 gene
features, the Random Forest mean decrease in accuracy is
used.74
In silico prognostic association assessments of mediator
expression signatures
This study capitalizes on publicly available datasets accessed
through a publicly available online survival analysis tool.
The KM-Plotter platform was employed in order to interro-
gate survival-associated biomarkers in ovarian cancer using
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microarray data and assess the impact of single immune
markers and marker combinations on patient survival in
ovarian cancer (Link to KM-Plotter platform http://kmplot.
com/analysis/index.php?p=service&cancer=ovar).75 Available
data encompassed Gene Expression Omnibus (GEO) and
The Cancer Genome Atlas (TCGA) datasets, which provided
microarray-generated intratumoral gene expression informa-
tion from Affymetrix platforms GPL96 (Affymetrix HG-
U133A), GPL570 (Affymetrix HG-U133 Plus 2.0) and
GPL571/GPL3921 (Affymetrix HG-U133A 2.0). These are
linked with survival data for 13,435 markers and tumor speci-
mens from 1,656 ovarian carcinoma patients linked with over-
all survival (OS) data, updated from 1,287 samples included in
the original report.75 Only publications with available raw
data, clinical survival information and at least 20 patients
were included in the cohort.75 Most tissue samples were
collected from patients with advanced ovarian cancers who
had undergone surgical debulking, a procedure commonly
used to treat ovarian tumors.76
Patients were stratified into two risk groups based on
expression levels of the selected mediator or of the combina-
tion of two, three, or four mediators; one group included
subjects with the top 25% of expression of the mediator(s),
whilst the second group included all other patients with lower
expression in their tumors. The effects of differential expres-
sion on overall patient survival were assessed by Kaplan
Meier-plots displaying the proportion of individuals surviving
in each cohort over a course of 5 years. Hazard ratios (HR),
95% confidence intervals and P-values (<0.05 considered to be
statistically significant) were calculated for all interrogated
signatures. Optimal probe sets were filtered by the JetSet
method which allowed selection of the most representative
probe sets for each gene and was used for all evaluations to
select for specificity, coverage and degradation resistance of
probes and enhance consistency and maximize data
accuracy.75 Batch effects were accounted for through
a double normalization of microarray chip-derived data:
a MAS5 algorithm-based normalization on individual-chip
level followed by scaling normalization to set the average
expression on each chip to 1,000. Analyses in the KM-
Plotter accounted for censored data, including losses from
the patient cohort over the follow-up threshold. Due to the
exploratory nature of our analysis and in order to avoid
increasing type II error (false negatives), results reported
by KM plotter are reported as provided by the KM plotter
resource without correction for multiple testing.77
A total of 1,978 single and combinations of secreted media-
tors were investigated derived from the 44 genes: 231 tests where
two mediators were combined, 591 tests where three mediators
were combined, and 1,112 tests where four mediators were
combined. All possible combinations of up to four were inves-
tigated within each immunity category (Supplementary Figure
1). In order to investigate the impact of each combination of
mediator expression, we employed the “multigene classifier” and
“mean expression of selected probes” functions provided by
the KM plotter. This enabled us to create a signature which is
the mean expression of selected genes, e.g. expression of gene (A
+ B + C)/3 = signature; which was then used to assess the impact
on overall survival.
Inflammation markers in sera of patients with ovarian
cancer in the AMORIS database
Study population and data collection
The Swedish Apolipoprotein MOrtality-related RISk (AMORIS)
cohort consists of participants predominantly living in greater
Stockholm in Sweden during the baseline period 1985–1996. At
the time of inclusion, all participants were either healthy indivi-
duals referred for a health check-up by their employers or were
outpatients. Between 1985 and 1996, over 500 different blood
biomarkers had been measured in 812,073 individuals. The
blood samples were analyzed at the Central Automation
Laboratory (CALAB) in Stockholm. With the use of a 10-digit
personal identification code used for all residents of Sweden, the
AMORIS cohort was linked with a variety of national registers.
Of particular importance for the present study, this linkage
included the Swedish national cancer register and cause of
death register, respectively. This enabled a basically complete
follow-up of incident (new) cases of cancer and cause specific
death until the end of follow-up in 2011. Additional national
registers provide data on education, socio-economic status,
comorbidities and emigration. The AMORIS cohort and its
linkages has been described in a cohort paper recently
published.21 The current study conformed to the declaration of
Helsinki and was approved by the ethics board of Karolinska
Institutet.
We included all individuals who had a diagnosis of ovarian
cancer (International Classification of Disease (ICD), Revision
7 (1995) code 175) and serum CRP measured between 6 days
and 5 years before the diagnosis of ovarian cancer (n = 289).
Measurements of serum albumin (n = 277), haptoglobin (n =
176) and white blood cells (n = 151) were also taken into
account when available. Follow-up time was defined as the
time from date of ovarian cancer diagnosis until date of death
or end of the study (31st December 2011), whichever occurred
first. The outcome evaluated was ovarian cancer-specific
death (ICD 9/10 code 183, C56). We included the following
information from the AMORIS study: serum CRP (mg/L),
albumin (g/L), leukocytes (x109 cells/L), haptoglobin (g/L)
and age at ovarian cancer diagnosis.
The quantitative determination of serum CRP and haptoglo-
bin was measured with an immunoturbi-dimetric assay
(reagents from Orion Diagnostics, Espoo, Finland) using fully
automated multichannel analyses (for CRP an AutoChemist –
PRISMA, New Clinicon, Stockholm, Sweden 1985–1992 and
a DAX 96, Technicon Instruments, Corporation, Tarrytown,
NY, USA, 1993–1996; for haptoglobin Hitachi-analysers,
Boehringer Mannheim, Baden-Wurttemberg, Germany). High
sensitivity CRP was not available during the period of blood
sample collection (1985–1996). Therefore, CRP < 10 mg/L
could not be measured precisely. However, the 10 mg/L cut-
off has been widely accepted as the upper limit of the health-
associated reference range. Albumin was measured using the
bromocresol green method. Leukocytes were measured by rou-
tinely used hematology analyzers (STKS Haematology System
from Coulter Corporation, Hialeah, FL). Total imprecision cal-
culated by the coefficient of variation was 12% at CRP level
40 mg/L, 5.6% at haptoglobin level 1.1 g/L, <1.8% for albumin
and <2.7% at leukocytes 10 × 109 cells/L.78
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Statistical analysis
We estimated the risk of ovarian cancer-specific death with
Cox proportional hazards regression for medical cut-offs used
in the CALAB laboratory for CRP: <10 mg/L and ≥10 mg/L;
haptoglobin: <1.4 g/L and ≥1.4 g/L; leukocytes: <10x109 cells/
L and ≥10x109 cells/L.79 Albumin was dichotomized as <40 g/
L and ≥40 g/L instead of the medical cut-off of 35 g/L due to
the small number of participants with low albumin levels.80
All models were adjusted for age. We additionally created
a Kaplan–Meier curve to graphically represent those associa-
tions observed to be statistically significant in the Cox models.
All statistical analyses were conducted with Statistical Analysis
Systems (SAS) release 9.4 (SAS Institute, Cary, NC).
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